EP3373958A4 - Proteasome modulation for treatment of corneal disorders - Google Patents
Proteasome modulation for treatment of corneal disorders Download PDFInfo
- Publication number
- EP3373958A4 EP3373958A4 EP16865148.7A EP16865148A EP3373958A4 EP 3373958 A4 EP3373958 A4 EP 3373958A4 EP 16865148 A EP16865148 A EP 16865148A EP 3373958 A4 EP3373958 A4 EP 3373958A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- corneal disorders
- proteasome modulation
- proteasome
- modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562255338P | 2015-11-13 | 2015-11-13 | |
PCT/US2016/061656 WO2017083741A1 (en) | 2015-11-13 | 2016-11-11 | Proteasome modulation for treatment of corneal disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3373958A1 EP3373958A1 (en) | 2018-09-19 |
EP3373958A4 true EP3373958A4 (en) | 2019-05-22 |
Family
ID=58695496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16865148.7A Withdrawn EP3373958A4 (en) | 2015-11-13 | 2016-11-11 | Proteasome modulation for treatment of corneal disorders |
Country Status (7)
Country | Link |
---|---|
US (1) | US10736934B2 (en) |
EP (1) | EP3373958A4 (en) |
JP (1) | JP2018533590A (en) |
KR (1) | KR20180080310A (en) |
CN (1) | CN108430496A (en) |
AU (1) | AU2016353333A1 (en) |
WO (1) | WO2017083741A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030086986A1 (en) | 1998-08-06 | 2003-05-08 | Bruijn Chris De | Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives |
AU2003291356A1 (en) * | 2002-11-06 | 2004-06-03 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
EA008496B1 (en) * | 2002-12-20 | 2007-06-29 | Чакшу Рисерч, Инк. | Ophthalmic formulation for the prevention and treatment of ocular conditions |
US9993558B2 (en) * | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
JP2009500297A (en) * | 2005-06-08 | 2009-01-08 | セントカー・インコーポレーテツド | Cell therapy for ocular degeneration |
CN103619327A (en) * | 2010-12-29 | 2014-03-05 | 嘉德治疗股份有限公司 | Ocular drug delivery system |
-
2016
- 2016-11-11 US US15/775,728 patent/US10736934B2/en active Active
- 2016-11-11 AU AU2016353333A patent/AU2016353333A1/en not_active Abandoned
- 2016-11-11 CN CN201680077903.7A patent/CN108430496A/en active Pending
- 2016-11-11 EP EP16865148.7A patent/EP3373958A4/en not_active Withdrawn
- 2016-11-11 JP JP2018522956A patent/JP2018533590A/en active Pending
- 2016-11-11 WO PCT/US2016/061656 patent/WO2017083741A1/en active Application Filing
- 2016-11-11 KR KR1020187016249A patent/KR20180080310A/en active IP Right Grant
Non-Patent Citations (7)
Title |
---|
BARDAG-GORCE F ET AL: "Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease", EXPERIMENTAL AND MOLECULAR PATHOLOGY, ACADEMIC PRESS, US, vol. 90, no. 1, 29 October 2009 (2009-10-29), pages 123 - 130, XP027582145, ISSN: 0014-4800, [retrieved on 20101029] * |
CHOI SEUNG-IL ET AL: "Autophagy is induced by raptor degradation via the ubiquitin/proteasome system in granular corneal dystrophy type 2", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 450, no. 4, 17 July 2014 (2014-07-17), pages 1505 - 1511, XP029044918, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2014.07.035 * |
ESTEY ET AL: "ALDH3A1: a corneal crystallin with diverse functions", EXPERIMENTAL EYE RESEA, ACADEMIC PRESS LTD, LONDON, vol. 84, no. 1, 25 November 2006 (2006-11-25), pages 3 - 12, XP005727360, ISSN: 0014-4835, DOI: 10.1016/J.EXER.2006.04.010 * |
EUI SEOK HAN ET AL: "Long-term outcome and prognostic factor analysis for keratolimbal allografts", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY ; INCORPORATING GERMAN JOURNAL OF OPHTHALMOLOGY, SPRINGER, BERLIN, DE, vol. 249, no. 11, 12 August 2011 (2011-08-12), pages 1697 - 1704, XP019968688, ISSN: 1435-702X, DOI: 10.1007/S00417-011-1760-3 * |
KLINGENSTEIN ET AL: "Decrease in Bilateral Corneal Deposits After Bortezomib/ Dexamethasone Chemotherapy in Monoclonal Gammopathy: Case Report", JOURNAL OF ANALYTICAL ONCOLOGY, vol. 1, 25 June 2012 (2012-06-25), pages 103 - 106, XP055579685, DOI: 10.6000/1927-7229.2012.01.01.15 * |
See also references of WO2017083741A1 * |
SHENG-MIN HSU ET AL: "Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis", MEDIATORS OF INFLAMMATION., vol. 2015, 7 September 2014 (2014-09-07), GB, pages 1 - 10, XP055580096, ISSN: 0962-9351, DOI: 10.1155/2015/847373 * |
Also Published As
Publication number | Publication date |
---|---|
US10736934B2 (en) | 2020-08-11 |
WO2017083741A1 (en) | 2017-05-18 |
KR20180080310A (en) | 2018-07-11 |
CN108430496A (en) | 2018-08-21 |
US20180369316A1 (en) | 2018-12-27 |
EP3373958A1 (en) | 2018-09-19 |
AU2016353333A1 (en) | 2018-06-21 |
JP2018533590A (en) | 2018-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1231417A1 (en) | Compounds for treating ophthalmic diseases and disorders | |
EP3212233A4 (en) | Combination therapy for treatment of disease | |
EP3177732A4 (en) | Compositions and methods for the treatment of ophthalmic diseases and conditions | |
EP3110417A4 (en) | Amino compounds for treatment of complement mediated disorders | |
EP3122878A4 (en) | Mrna therapy for the treatment of ocular diseases | |
EP3185876A4 (en) | Compositions and methods for treatment of neurological disorders | |
EP3157463A4 (en) | Methods and devices for treating posterior ocular disorders | |
EP3240612A4 (en) | Methods of treating retinal diseases | |
EP3374502A4 (en) | Methods for the treatment of corneal dystrophies | |
EP3137481A4 (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
EP3191185A4 (en) | Device for targeted treatment of dermastoses | |
EP3215148A4 (en) | Methods for treatment of cognitive decline | |
RS61504B1 (en) | Heteroaryl compounds for the treatment of ophthalmic diseases | |
EP3209732A4 (en) | Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders | |
EP3554505A4 (en) | Methods of treating ocular disorders | |
EP3340974A4 (en) | Methods for treatment of diseases | |
IL258593A (en) | Compounds for treatment of hypoproliferative disorders | |
EP3370709A4 (en) | Use of proteasome inhibitors to treat ocular disorders | |
EP3213762A4 (en) | Novel treatment of cornea using laminin | |
EP3209295A4 (en) | Methods of treating ocular conditions | |
EP3302382A4 (en) | Implant for treatment of an ocular condition | |
IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
PT3407879T (en) | Ophthalmic gabapentin for the treatment of corneal ulcers | |
EP3229908A4 (en) | Gdnf induction for the treatment of retinal disorders | |
EP3271017A4 (en) | Treatment of skin conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180604 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190423 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/55 20060101AFI20190415BHEP Ipc: A61P 27/02 20060101ALI20190415BHEP Ipc: A61K 31/00 20060101ALI20190415BHEP Ipc: A61K 38/16 20060101ALI20190415BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200507 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20200821 |